http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 10 Jun 2026 07:55:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="Frankfurt:2F5" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended <chron>March 31, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1069511/Scinai_Immunotherapeutics_Logo.jpg?id=OA2695551" http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html Wed, 10 Jun 2026 07:55:00 -0400 2F5 2F5.MU A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="Frankfurt:2F5" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended <chron>March 31, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1069511/Scinai_Immunotherapeutics_Logo.jpg?id=OA2695551" http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html Wed, 10 Jun 2026 07:55:00 -0400 2F5 2F5.MU A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="Frankfurt:2F5" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended <chron>March 31, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1069511/Scinai_Immunotherapeutics_Logo.jpg?id=OA2695551" http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html Wed, 10 Jun 2026 07:55:00 -0400 2F5 2F5.MU A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="Frankfurt:2F5" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended <chron>March 31, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1069511/Scinai_Immunotherapeutics_Logo.jpg?id=OA2695551" http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html Wed, 10 Jun 2026 07:55:00 -0400 2F5 2F5.MU A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="Frankfurt:2F5" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended <chron>March 31, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1069511/Scinai_Immunotherapeutics_Logo.jpg?id=OA2695551" http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html Wed, 10 Jun 2026 07:55:00 -0400 2F5 2F5.MU A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="Frankfurt:2F5" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended <chron>March 31, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1069511/Scinai_Immunotherapeutics_Logo.jpg?id=OA2695551" http://www.streetinsider.com/Press+Releases/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html Wed, 10 Jun 2026 07:55:00 -0400 2F5 2F5.MU A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="Frankfurt:2F5" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended <chron>March 31, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1069511/Scinai_Immunotherapeutics_Logo.jpg?id=OA2695551" http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html Wed, 10 Jun 2026 07:55:00 -0400 2F5 2F5.MU A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="Frankfurt:2F5" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended <chron>March 31, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1069511/Scinai_Immunotherapeutics_Logo.jpg?id=OA2695551" http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html Wed, 10 Jun 2026 07:55:00 -0400 2F5 2F5.MU A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="Frankfurt:2F5" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended <chron>March 31, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1069511/Scinai_Immunotherapeutics_Logo.jpg?id=OA2695551" http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html Wed, 10 Jun 2026 07:55:00 -0400 2F5 2F5.MU A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="Frankfurt:2F5" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended <chron>March 31, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1069511/Scinai_Immunotherapeutics_Logo.jpg?id=OA2695551" http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html Wed, 10 Jun 2026 07:55:00 -0400 2F5 2F5.MU A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="Frankfurt:2F5" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended <chron>March 31, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1069511/Scinai_Immunotherapeutics_Logo.jpg?id=OA2695551" http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html Wed, 10 Jun 2026 07:55:00 -0400 2F5 2F5.MU A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="Frankfurt:2F5" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended <chron>March 31, 2026</chron> and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1069511/Scinai_Immunotherapeutics_Logo.jpg?id=OA2695551" http://www.streetinsider.com/PRNewswire/Scinai+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update+Highlighting+Expansion+of+CDMO+Platform+and+Advancement+of+Strategic+Growth+Initiatives/26626830.html Wed, 10 Jun 2026 07:55:00 -0400 2F5 2F5.MU A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Scinai+Immunotherapeutic++For%3A+Jun+08/26616326.html si-local-file:///var/storage/secattach/20260608/26616326.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Scinai+Immunotherapeutic++For%3A+Jun+08/26616326.html Mon, 08 Jun 2026 12:57:00 -0400 2F5 O.05713057 SCNI http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Scinai+Immunotherapeutic++For%3A+Jun+08/26616326.html si-local-file:///var/storage/secattach/20260608/26616326.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Scinai+Immunotherapeutic++For%3A+Jun+08/26616326.html Mon, 08 Jun 2026 12:57:00 -0400 2F5 O.05713057 SCNI http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Scinai+Immunotherapeutic++For%3A+Jun+08/26616326.html si-local-file:///var/storage/secattach/20260608/26616326.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Scinai+Immunotherapeutic++For%3A+Jun+08/26616326.html Mon, 08 Jun 2026 12:57:00 -0400 2F5 O.05713057 SCNI http://www.streetinsider.com/Corporate+News/Scinai+Biopharma+Services+names+Eilon+Elmalem+head+of+Yavne+facility/26524654.html <p>Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that its subsidiary Scinai Biopharma Services Ltd. has appointed Eilon Elmalem as Site Head of its Yavne contract development and manufacturing organization facility, effective June 14.</p><p>Elmalem has worked with Scinai as an external consultant for two years, supporting the company's CDMO activities and operational development. He was involved in transition and operational integration planning of the Yavne facility.</p><p>The executive brings more than 20 years of experience in engineering, operations, process development, and industrial infrastructure management within biotechnology and pharmaceutical industries. He previously held senior leadership roles at Merck and Sigma-Aldrich Millipore, including VP of http://www.streetinsider.com/Corporate+News/Scinai+Biopharma+Services+names+Eilon+Elmalem+head+of+Yavne+facility/26524654.html Wed, 20 May 2026 07:00:54 -0400 SCNI http://www.streetinsider.com/Management+Changes/Scinai+Biopharma+Services+names+Eilon+Elmalem+head+of+Yavne+facility/26524654.html <p>Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that its subsidiary Scinai Biopharma Services Ltd. has appointed Eilon Elmalem as Site Head of its Yavne contract development and manufacturing organization facility, effective June 14.</p><p>Elmalem has worked with Scinai as an external consultant for two years, supporting the company's CDMO activities and operational development. He was involved in transition and operational integration planning of the Yavne facility.</p><p>The executive brings more than 20 years of experience in engineering, operations, process development, and industrial infrastructure management within biotechnology and pharmaceutical industries. He previously held senior leadership roles at Merck and Sigma-Aldrich Millipore, including VP of http://www.streetinsider.com/Management+Changes/Scinai+Biopharma+Services+names+Eilon+Elmalem+head+of+Yavne+facility/26524654.html Wed, 20 May 2026 07:00:54 -0400 SCNI http://www.streetinsider.com/Press+Releases/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ – <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:SCNI" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, <span><a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span>Scinai Biopharma Services Ltd</span></a>.</span>, a contract development and manufacturing organization (CDMO), has appointed Mr. <person>Eilon Elmalem</person> as Site Head of its Yavne CDMO facility, effective <chron>June 14, 2026</chron>.</p> <div id="prni_dvprnejpg230eleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg230eleft" title="Scinai Immunotherapeutics Logo" src="https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg" alt="Scinai Immunotherapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2310190%2FScinai_Immunotherapeutics_Logo.jpg" /></div><p><person>Mr. Elmalem</person> has worked with http://www.streetinsider.com/Press+Releases/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html Wed, 20 May 2026 07:00:00 -0400 A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/Press+Releases/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ – <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:SCNI" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, <span><a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span>Scinai Biopharma Services Ltd</span></a>.</span>, a contract development and manufacturing organization (CDMO), has appointed Mr. <person>Eilon Elmalem</person> as Site Head of its Yavne CDMO facility, effective <chron>June 14, 2026</chron>.</p> <div id="prni_dvprnejpg230eleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg230eleft" title="Scinai Immunotherapeutics Logo" src="https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg" alt="Scinai Immunotherapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2310190%2FScinai_Immunotherapeutics_Logo.jpg" /></div><p><person>Mr. Elmalem</person> has worked with http://www.streetinsider.com/Press+Releases/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html Wed, 20 May 2026 07:00:00 -0400 A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/Press+Releases/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ – <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:SCNI" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, <span><a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span>Scinai Biopharma Services Ltd</span></a>.</span>, a contract development and manufacturing organization (CDMO), has appointed Mr. <person>Eilon Elmalem</person> as Site Head of its Yavne CDMO facility, effective <chron>June 14, 2026</chron>.</p> <div id="prni_dvprnejpg230eleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg230eleft" title="Scinai Immunotherapeutics Logo" src="https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg" alt="Scinai Immunotherapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2310190%2FScinai_Immunotherapeutics_Logo.jpg" /></div><p><person>Mr. Elmalem</person> has worked with http://www.streetinsider.com/Press+Releases/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html Wed, 20 May 2026 07:00:00 -0400 A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/Press+Releases/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ – <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:SCNI" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, <span><a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span>Scinai Biopharma Services Ltd</span></a>.</span>, a contract development and manufacturing organization (CDMO), has appointed Mr. <person>Eilon Elmalem</person> as Site Head of its Yavne CDMO facility, effective <chron>June 14, 2026</chron>.</p> <div id="prni_dvprnejpg230eleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg230eleft" title="Scinai Immunotherapeutics Logo" src="https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg" alt="Scinai Immunotherapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2310190%2FScinai_Immunotherapeutics_Logo.jpg" /></div><p><person>Mr. Elmalem</person> has worked with http://www.streetinsider.com/Press+Releases/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html Wed, 20 May 2026 07:00:00 -0400 A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/PRNewswire/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ – <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:SCNI" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, <span><a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span>Scinai Biopharma Services Ltd</span></a>.</span>, a contract development and manufacturing organization (CDMO), has appointed Mr. <person>Eilon Elmalem</person> as Site Head of its Yavne CDMO facility, effective <chron>June 14, 2026</chron>.</p> <div id="prni_dvprnejpg230eleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg230eleft" title="Scinai Immunotherapeutics Logo" src="https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg" alt="Scinai Immunotherapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2310190%2FScinai_Immunotherapeutics_Logo.jpg" /></div><p><person>Mr. Elmalem</person> has worked with http://www.streetinsider.com/PRNewswire/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html Wed, 20 May 2026 07:00:00 -0400 A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/PRNewswire/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ – <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:SCNI" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, <span><a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span>Scinai Biopharma Services Ltd</span></a>.</span>, a contract development and manufacturing organization (CDMO), has appointed Mr. <person>Eilon Elmalem</person> as Site Head of its Yavne CDMO facility, effective <chron>June 14, 2026</chron>.</p> <div id="prni_dvprnejpg230eleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg230eleft" title="Scinai Immunotherapeutics Logo" src="https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg" alt="Scinai Immunotherapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2310190%2FScinai_Immunotherapeutics_Logo.jpg" /></div><p><person>Mr. Elmalem</person> has worked with http://www.streetinsider.com/PRNewswire/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html Wed, 20 May 2026 07:00:00 -0400 A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/PRNewswire/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ – <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:SCNI" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, <span><a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span>Scinai Biopharma Services Ltd</span></a>.</span>, a contract development and manufacturing organization (CDMO), has appointed Mr. <person>Eilon Elmalem</person> as Site Head of its Yavne CDMO facility, effective <chron>June 14, 2026</chron>.</p> <div id="prni_dvprnejpg230eleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg230eleft" title="Scinai Immunotherapeutics Logo" src="https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg" alt="Scinai Immunotherapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2310190%2FScinai_Immunotherapeutics_Logo.jpg" /></div><p><person>Mr. Elmalem</person> has worked with http://www.streetinsider.com/PRNewswire/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html Wed, 20 May 2026 07:00:00 -0400 A.50113769 O.00624550 O.05713057 SCNI http://www.streetinsider.com/PRNewswire/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/il..jerusl" idsrc="xmltag.org" >JERUSALEM</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ – <a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:SCNI" idsrc="xmltag.org" >Scinai Immunotherapeutics Ltd</span></a>. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, <span><a target="_blank" href="https://www.scinai.com/cdmo" target="_blank" rel="nofollow"><span>Scinai Biopharma Services Ltd</span></a>.</span>, a contract development and manufacturing organization (CDMO), has appointed Mr. <person>Eilon Elmalem</person> as Site Head of its Yavne CDMO facility, effective <chron>June 14, 2026</chron>.</p> <div id="prni_dvprnejpg230eleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg230eleft" title="Scinai Immunotherapeutics Logo" src="https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg" alt="Scinai Immunotherapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2310190%2FScinai_Immunotherapeutics_Logo.jpg" /></div><p><person>Mr. Elmalem</person> has worked with http://www.streetinsider.com/PRNewswire/Scinai+Biopharma+Services+Appoints+Eilon+Elmalem+as+Site+Head+of+Yavne+CDMO+Facility/26524613.html Wed, 20 May 2026 07:00:00 -0400 A.50113769 O.00624550 O.05713057 SCNI